BridgeBio Pharma Inc. Common Stock (BBIO)
Stock · NASDAQ · Health Care
$66.38as of 10/16/2026
Price chart
Active signals
Support Confirmation96.4%Revenue-Price Divergence (6M)51.7%RSI Positive Divergence13.8%200 SMA Touch0.0%
Support level
$65.57
Industry
Biotechnology: Pharmaceutical Preparations
BBIO Signal Track Record
How signals performed across all stocks →What BBIO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | -2.3% | 45% | September 24, 2026 |
| Bollinger Band Breakout | 27 | +0.3% | 52% | June 29, 2026 |
| Bollinger Band Breakdown | 18 | +9.7% | 72% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +4.8% | 58% | June 10, 2026 |
| Any 20-session window (baseline) | +2.3% | 56% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BBIO
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for t…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 999
- Website
- bridgebio.com/
Fundamentals
- 1-day range
- $65.26$67.04
- Market cap
- $16.20B
- P/E (trailing)
- —
- P/E (forward)
- -259.96
- EPS (trailing)
- $-3.57
- Dividend yield
- —
- Beta
- 0.95
- Avg. volume
- 2.39M
52-week range
$52.75$93.42
Next earnings: October 28, 2026 · EPS estimate $-0.58confirmed
How BridgeBio Pharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 24, 2026 · via SEC EDGAR / Finnhub
Gross Profit$481.11M(96%)
Operating Income-$523.41M(-104%)
Forecasts
22 analyst ratings
Buy 90%
Hold 10%
Sell 0%
1-year price forecast
High
$156
+135.0%
Median
$109
+64.2%
Low
$80
+20.5%
BridgeBio Pharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BBIOBridgeBio Pharma Inc. Common Stock$66.39▼ 1.10%Market cap $16.20BP/E —$52.75$93.42
- JAZZJazz Pharmaceuticals plc Common Stock (Ireland)$210.23▼ 1.95%Market cap $16.66BP/E 14.90$128.8$266.38
- ASNDAscendis Pharma A/S Ordinary Share$225.25▼ 0.60%Market cap $15.49BP/E 16.93$186.05$282.15
- VTRSViatris Inc. Common Stock$18.66▲ 2.41%Market cap $18.97BP/E —$9.73$18.43
- ARWRArrowhead Pharmaceuticals Inc. Common Stock$55.9▼ 4.44%Market cap $12.12BP/E —$36.02$95.49
- ELANElanco Animal Health Incorporated Common Stock$23.55▲ 0.04%Market cap $12.09BP/E —$19.4$27.98
- BMRNBioMarin Pharmaceutical Inc. Common Stock$54.68▼ 2.44%Market cap $11.88BP/E 151.14$49.26$70.98
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BBIO BridgeBio Pharma Inc. Common Stock | $16.20B | — | $66.39 | ▼ 1.10% | $52.75$93.42 |
| JAZZ Jazz Pharmaceuticals plc Common Stock (Ireland) | $16.66B | 14.90 | $210.23 | ▼ 1.95% | $128.8$266.38 |
| ASND Ascendis Pharma A/S Ordinary Share | $15.49B | 16.93 | $225.25 | ▼ 0.60% | $186.05$282.15 |
| VTRS Viatris Inc. Common Stock | $18.97B | — | $18.66 | ▲ 2.41% | $9.73$18.43 |
| ARWR Arrowhead Pharmaceuticals Inc. Common Stock | $12.12B | — | $55.9 | ▼ 4.44% | $36.02$95.49 |
| ELAN Elanco Animal Health Incorporated Common Stock | $12.09B | — | $23.55 | ▲ 0.04% | $19.4$27.98 |
| BMRN BioMarin Pharmaceutical Inc. Common Stock | $11.88B | 151.14 | $54.68 | ▼ 2.44% | $49.26$70.98 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Reported Sunday, BridgeBio’s Encaleret Raises Bone Turnover, With 100% Of Phase 3 CALIBRATE Participants Reporting Improvement In At Least One ADH1 Symptom Versus 46% On Standard Of Carebenzinga · 10/12/2026
- FDA Grants Priority Review to BridgeBio's Dwarfism Drug FilingYahoo · 10/7/2026
- Barclays Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $156Benzinga · 10/7/2026
- BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual MeetingYahoo · 10/6/2026
- BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026Yahoo · 10/6/2026
- BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis DayYahoo · 10/6/2026
- BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with AchondroplasiaYahoo · 10/6/2026
- BridgeBio Pharma Receives FDA Acceptance For Filing Its New Drug Application With Priority Review For Oral Infigratinib To Treat AchondroplasiaBenzinga · 10/6/2026
- BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected LevelsYahoo · 10/5/2026
Insider Activity
Insider Actions →Acquired
71.2K
Disposed
82.5K
- Neil Kumar · September 17, 2026 · Sale1.3K @ $69.57
- Neil Kumar · September 17, 2026 · Sale8.7K @ $69.01
- Neil Kumar · August 19, 2026 · Sale100 @ $85.65
- Neil Kumar · August 19, 2026 · Sale1.8K @ $84.69
- Neil Kumar · August 19, 2026 · Sale8.1K @ $83.86
- Neil Kumar · August 18, 2026 · Sale1.2K @ $83.77
- Neil Kumar · August 18, 2026 · Sale14.6K @ $82.99
- Neil Kumar · August 18, 2026 · Sale17.3K @ $82.21
- Neil Kumar · August 18, 2026 · Sale1.9K @ $81.15
- Neil Kumar · August 16, 2026 · Option Exercise11.6K
- Thomas Trimarchi · August 16, 2026 · Tax Withholding22.8K @ $79.86
- Maricel Apuli · August 16, 2026 · Tax Withholding4.7K @ $79.86
- Neil Kumar · August 16, 2026 · Option Exercise6.5K
- Neil Kumar · August 16, 2026 · Option Exercise19.6K
- Neil Kumar · August 16, 2026 · Option Exercise33.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 195.68M
- Total value held
- $14.01B
- Institutional holders
- 452
Top holders this quarter
- Unknown14.21M
- Unknown13.26M
- Unknown13.18M
- Unknown11.84M
- Unknown9.37M
- Unknown7.76M
- Unknown5.89M
- Unknown5.09M
- Unknown4.94M
- Unknown4.93M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
BridgeBio Reports Positive Phase 3 Data for Encaleret and Acoramidis
BridgeBio presented new data showing Encaleret improved symptoms in a Phase 3 trial for ADH1, with all participants reporting better outcomes than the standard of care. The company also shared real-world results for Acoramidis, indicating lower composite risk compared to tafamidis in ATTR-CM patients. These updates follow a recent 28% drop in the stock, which analysts suggest may be undervalued relative to their average target price.
BridgeBio Reports Positive Phase 3 Data for Encaleret and Acoramidis. BridgeBio presented new data showing Encaleret improved symptoms in a Phase 3 trial for ADH1, with all participants reporting better outcomes than the standard of care. The company also shared real-world results for Acoramidis, indicating lower composite risk compared to tafamidis in ATTR-CM patients. These updates follow a recent 28% drop in the stock, which analysts suggest may be undervalued relative to their average target price.